SCHEMBL11977551

SCHEMBL11977551

c1ccc(-c2nnc(-c3ccc(-c4ccc(-c5nnc(-c6ccccc6)o5)cc4-c4ccccc4)c(-c4ccccc4)c3)o2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 16/20 0.65
▸ RAB9A P51151 16/20 0.65
▸ SMN1; SMN2 Q16637 10/20 0.65
▸ HPGD P15428 6/20 0.58
▸ NFKB1 P19838 2/20 0.58
▸ NFKB2 Q00653 2/20 0.58
▸ RELA Q04206 2/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ POLB P06746 1/20 0.58
▸ TSHR P16473 5/20 0.58
▸ TP53 P04637 3/20 0.58
▸ MECP2 P51608 1/20 0.58
▸ ALDH1A1 P00352 6/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ MAPT P10636 2/20 0.56
▸ GLA P06280 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343181 0.83 NPC1 (0.94) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL19976610 0.83 NPC1 (0.49) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL14378791 0.81 NPC1 (0.81) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL522555 0.81 NPC1 (0.90) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL46424 0.81 NPC1 (0.90) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL74999 0.81 NPC1 (0.90) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL22858502 0.81 NPC1 (0.90) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL46426 0.81 NPC1 (1.00) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL2729306 0.81 RAB9A (0.60) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL34467620 0.81 RAB9A (0.46) NPC1RAB9ASMN1; SMN2HPGDNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9437828-B2 Electroluminescent device using azomethine-lithium-complex as electron injection layer MERCK PATENT GMBH (DE) 2016-09-06 — — US disclosed
US-9437828-B2 Electroluminescent device using azomethine-lithium-complex as electron injection layer MERCK PATENT GMBH (DE) 2016-09-06 — — US disclosed
US-9252383-B2 Cathode coating MERCK PATENT GMBH (DE) 2016-02-02 — — US disclosed
US-9252383-B2 Cathode coating MERCK PATENT GMBH (DE) 2016-02-02 — — US disclosed
US-20150065725-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2015-03-05 — — US disclosed
US-20150065725-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2015-03-05 — — US disclosed
US-8883325-B2 Electroluminescent device using azomethine-lithium-complex as electron injection layer MERCK PATENT GMBH (DE) 2014-11-11 — — US disclosed
US-8883325-B2 Electroluminescent device using azomethine-lithium-complex as electron injection layer MERCK PATENT GMBH (DE) 2014-11-11 — — US disclosed
US-20120205638-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2012-08-16 — — US disclosed
US-20120205638-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2012-08-16 — — US disclosed
US-20100327264-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATNET GMBH (DE) 2010-12-30 — — US disclosed
US-20100327264-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATNET GMBH (DE) 2010-12-30 — — US disclosed
US-20100289009-A1 CATHODE COATING MERCK PATENT GMBH (DE) 2010-11-18 — — US disclosed
US-20100289009-A1 CATHODE COATING MERCK PATENT GMBH (DE) 2010-11-18 — — US disclosed
WO-2008012581-A2 CATHODE COATING MERCK PATENT GMBH (DE) 2008-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120205638-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER ACSL3, APOL1, INTS9 NPC1 1103/4885RAB9A 2201/4885SMN1; SMN2 4597/4885
US-20100327264-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER ACSL3, APOL1, INTS9 NPC1 1206/4885RAB9A 2166/4885SMN1; SMN2 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback